Shares of G1 Therapeutics Inc. (GTHX) rose more than 19% in after-hours on Monday, following positive regulatory update on Trilaciclib, an intravenous CDK4/6 inhibitor in development, to reduce *myelosuppression and enhance immune system function during chemotherapy.
from RTT - Biotech http://bit.ly/2UJlHEU
via IFTTT
No comments:
Post a Comment